RazI, HanefelM, XuL. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia2006; 49:2564–71.
2.
AschnerP, KipnesMS, LuncefordJK. Effects of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care2006; 29:2632–7.
3.
CharbonnelB, KarasikA, LiuJ. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care2006; 29:2638–43.
4.
GoldsteinBJ, FeinglosMN, LuncefordJK. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007; 30:1979–87.
5.
NauckMA, MeiningerG, ShengD, TerranellaL, SteinPP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab2007; 9:194–205.
